samedan logo
 
 
 
spacer
home > pmps > autumn 2020 > the future of the pharma ecosystem post-covid-19
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Future of the Pharma Ecosystem Post-COVID-19

The ongoing global pandemic has caused complete upheaval across the world for individuals and businesses alike. Within the pharmaceutical and life science industry, the need to develop a vaccine quickly is putting immense pressure on a workforce that is arguably already stretched, as skills shortages continue to have an effect on resources. However, while the pandemic has certainly presented a number of challenges, it has also created opportunities that have the potential to help alleviate many long-standing recruitment barriers.

So, what impact has COVID-19 had on talent acquisition across the life science and pharma industry?

A Changing Talent Landscape

STEM skills shortages have been widely discussed for some time now, and anyone in the pharma or life science arena will certainly be acutely aware of the talent challenges facing almost every firm in the field. The simple truth is that following a career in STEM-related professions doesn’t appeal to enough individuals in education to ensure a steady stream of newly trained recruits to meet demand on a global scale. With digital skills in limited supply, but high demand across almost every sector, attracting tech talent into pharma and the life science industry isn’t easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Jim Sykes has 20 years’ experience in talent acquisition and holds significant international experience, having supported clients and managed teams on a global basis. He is responsible for client relationships and delivery within the pharma and life science sector and the professional and business services sector at Alexander Mann Solutions.
spacer
Jim Sykes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Peptilogics Closes $35.4 Million Series B Financing to Further Advance Proprietary Computational Peptide Drug Design and Discovery Platform

PITTSBURGH, PA, Dec. 21, 2020 /PRNewswire/ -- Peptilogics announced today the closing of a $35.4 million Series B financing. The financing was led by Presight Capital, with participation from a new investor syndicate including Founders Fund as well as from existing investor Peter Thiel. The proceeds of the financing will be used to expand Peptilogics’ computational platform and invest in technologies to improve its drug design engine, as well as accelerate development of a pipeline of peptide therapeutics including the Company’s lead clinical asset, PLG0206, which has demonstrated first-in-class safety and best-in-class efficacy.
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement